Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. director and 10% owner James B. Tananbaum filed a Form 4 reporting indirect ownership changes through investment entities. On January 8, 2026, entities associated with him purchased 117,647 and 294,117 shares of Alumis common stock at $17 per share, reported as indirect acquisitions. The filing also lists sizable indirect holdings in Alumis common stock by multiple Foresite Capital and Foresite Labs funds and LLCs, including Foresite Capital Fund V, Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. The footnotes state that these entities hold the shares of record and that Tananbaum may be deemed to share or have voting and dispositive power, while he disclaims beneficial ownership except for his pecuniary interest.
Alumis Inc. reported that its preliminary unaudited cash, cash equivalents and marketable securities totaled approximately $308.6 million as of December 31, 2025. This figure is management’s estimate and has not been audited, reviewed or examined by PricewaterhouseCoopers LLP and may change once the quarter- and year-end closing process is completed.
The company also entered into an underwriting agreement for a public offering of 17,650,000 shares of its common stock at $17.00 per share$345.1 million before underwriting discounts, commissions and expenses. The offering is expected to close on January 9, 2026, and the underwriters’ 30‑day option to purchase up to 2,647,500 additional shares was exercised in full on January 8, 2026.
Alumis Inc. is offering 17,650,000 shares of its common stock at $17.00 per share, for gross proceeds of $300,050,000 and estimated net proceeds of about $281.5 million. The company has also granted underwriters a 30‑day option to buy up to 2,647,500 additional shares. Alumis plans to use the cash, together with existing funds, to support a planned NDA filing and launch preparations for its TYK2 inhibitor envu in plaque psoriasis, advance envu and other pipeline programs, and for general corporate purposes.
The company recently reported positive Phase 3 ONWARD1 and ONWARD2 results for envu in moderate‑to‑severe plaque psoriasis, with 74% of patients achieving PASI 75 and 59% achieving sPGA 0/1 at Week 16 on average across both trials, and strong PASI 90/100 responses by Week 24. Based on preliminary estimates, Alumis had approximately $308.6 million in cash, cash equivalents and marketable securities as of December 31, 2025, but its disclosures note substantial doubt about its ability to continue as a going concern without significant additional capital. After this offering, Alumis expects to fund operations into the fourth quarter of 2027, though investors will face immediate and substantial dilution.
Alumis Inc. filed a report describing new communications about its oral psoriasis therapy envudeucitinib. The company issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program” and furnished it as an exhibit. Alumis also posted an updated corporate presentation for investors and attached it as a separate exhibit.
The report notes that these materials contain forward-looking statements, including Alumis’s plans to submit a new drug application in the second half of 2026 and the potential for envudeucitinib to address IL-23/IL-17–driven diseases and those driven by Type I interferon. Alumis cautions that regulatory decisions, clinical trial outcomes, funding, and intellectual property protection could cause actual results to differ from these expectations.
Alumis Inc. (ALMS) disclosed an insider stock purchase on a Form 4. Investment entities affiliated with Foresite Capital, managed by James B. Tananbaum, reported buying 72,212 shares of Alumis common stock on 11/21/2025 in an open-market transaction coded "P" at a price of $7.38 per share.
After this trade, one reporting entity, Foresite Capital Opportunity Fund V, L.P., is shown as indirectly beneficially owning 2,614,215 shares of Alumis common stock, with additional indirect holdings reported through other Foresite-managed funds. The reporting persons state that each investment vehicle and manager disclaims being part of a group and disclaims beneficial ownership of shares held by the other funds beyond their economic interest.
Alumis Inc. (ALMS) insider James B. Tananbaum, a director and 10% owner, reported buying additional common stock through affiliated investment entities. On 11/21/2025, an indirect account purchased 72,212 Alumis common shares at a price of $7.38 per share, reported as an acquisition. After this transaction, multiple affiliated Foresite Capital and Foresite Labs funds and vehicles are shown as beneficially owning various blocks of Alumis stock, all reported as indirect ownership.
The filing explains that several limited partnerships and LLCs, including Foresite Capital Opportunity Fund V, Foresite Capital Fund V and VI, and multiple Foresite Labs vehicles, hold the shares of record. Management entities and Mr. Tananbaum may be deemed to have voting and dispositive power over these holdings, but he formally disclaims group status and beneficial ownership beyond his pecuniary interest in each entity.
Alumis Inc. (ALMS) reported an insider purchase by a director-affiliated entity. On 11/21/2025, a reporting person bought 72,212 shares of common stock at $7.38 per share, recorded as an indirect holding.
After this transaction, the reporting person reports indirect beneficial ownership of multiple large Alumis positions through affiliated Foresite investment vehicles. These include 2,614,215 shares held by Foresite Capital Opportunity Fund V, L.P., 4,247,670 shares held by Foresite Capital Fund VI, L.P., 5,584,889 shares held by Foresite Capital Fund V, L.P., and additional blocks of 194,459, 1,960,337, and 1,176,470 shares held by other Foresite-related entities.
The filing notes that the various Foresite funds and management entities, including James B. Tananbaum, may be deemed to share voting and dispositive power over these shares but each disclaims being part of a "group" and disclaims beneficial ownership beyond their pecuniary interests.
Alumis Inc. (ALMS) reported an insider share purchase on a Form 4 by a director associated with Samsara investment entities. On 11/20/2025, the reporting person, through Samsara Opportunity Fund, L.P., purchased 125,743 shares of common stock in an open-market transaction at a weighted average price of $7.20 per share, with individual trades occurring between $6.92 and $7.48. Following this transaction, Samsara Opportunity Fund, L.P. was shown as holding 643,260 shares indirectly attributed to the reporting person, and Samsara BioCapital, L.P. was shown as holding an additional 4,491,731 shares indirectly. The reporting person indicates that beneficial ownership of these positions is disclaimed except to the extent of any pecuniary interest.
Alumis Inc. (ALMS) reported insider share purchases by a director affiliated with Foresite entities. On 11/17/2025, the reporting person acquired 50,000 shares of common stock at $5.60 and 150,000 shares at $5.59. On 11/18/2025, a further 117,374 shares were purchased at $6.19, followed by 190,500 shares at $6.56 on 11/19/2025, all reported as indirect ownership.
After these transactions, the Form 4 shows 2,542,003 Alumis shares beneficially owned indirectly under footnote (1), with additional indirect beneficial holdings of 4,247,670, 5,584,889, 194,459, 1,960,337 and 1,176,470 shares through various Foresite Capital and Foresite Labs funds and entities, each with specified control structures and standard beneficial ownership disclaimers.
Alumis Inc. (ALMS) received a series of insider share purchases by Foresite-affiliated funds and entities whose managing member, James B. Tananbaum, serves as a director of the company. Between 11/17/2025 and 11/19/2025, these reporting persons purchased a combined 507,874 shares of Alumis common stock in open-market transactions at prices ranging from $5.60 to $6.56 per share.
After these transactions, the reporting persons report indirect beneficial ownership of several large blocks of Alumis stock, including 4,247,670 shares held by Foresite Capital Opportunity Fund V, L.P. and 5,584,889 shares held by Foresite Capital Fund VI, L.P., along with additional stakes held by related funds and co-investment vehicles as detailed in the footnotes.